Physician profile
Mitzi Amelon
NPI 1831140409
$1,436.93
in general payments reported to CMS, 2019-2025
20 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2022: $25.57 · 2023: $540 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $218.05 | 2019 | |
| Lilly USA, LLC | $158.86 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $138.32 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.63 | 2019-2023 | Tradjenta |
| Axsome Therapeutics, INC. | $124.82 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $116.10 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $94.85 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $93.11 | 2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $89.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.84 | 2023 | |
| Sunovion Pharmaceuticals INC. | $36.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.08 | 2023 | Breztri |
| Idorsia Pharmaceuticals US INC | $27.78 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $25.53 | 2023 | Rexulti |
| Amgen INC. | $19.59 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $18.14 | 2019 | |
| Exact Sciences Corporation | $15.59 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2019 | |
| Glaxosmithkline, LLC. | $12.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Amelon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.